沙利度胺辅助化疗治疗晚期非小细胞肺癌  

Thalidomide combined with chemotherapy in the treatment of advanced non-small cell lung cancer

作　　者：陈英[1] 

机构地区：[1]哈尔滨市阿城区人民医院内科

出　　处：《世界临床药物》2008年第12期736-740,共5页World Clinical Drug

摘　　要：目的观察沙利度胺辅助化疗对晚期非小细胞肺癌(NSCLC)的治疗作用。方法40例Karnofsky评分达到60分以上的NSCLC患者,随机分为治疗组(n=20)和对照组(n=20)。治疗组接受化疗联合沙利度胺治疗,对照组则仅接受化疗,两组化疗方案均为长春瑞滨+卡铂。以近期有效率和中位缓解期评价各组疗效。结果治疗组近期有效率和中位缓解期分别为61.1%和2.7月,对照组相应的为50.0%和2.4月,两组相比无显著差异(P>0.05)。结论沙利度胺辅助化疗用于晚期NSCLC耐受性良好,并具有一定的增效减毒作用。Objective To investigate the adjunctive effect of thalidomide on patients with advanced non-small cell lung cancer. Methods 40 patients with pathologically confirmed advanced non-small cell lung cancer were randomly divided into treatment group （n=20） and control group （n=20）, Karnofsky score of which were all above 60. Patients in treatment group were administered chemotherapy plus thalidomide and those in control group were administered chemotherapy only. Chemotherapeutics in two groups were both vinorelbine plus carboplatin. Response rate and median paracme were observed. Results The response rate and median paracme in treatment group and control group were 61.1%, 2.7 months and 50.0 %, 2.4 months respectively. There were no differences between two groups （P 〉 0.05）. Conclusion Thalidomide combined with chemotherapy can partly enhance the therapeutic effect in the treatment of advanced non-small cell lung cancer and reduce the adverse reaction of chemotherapy.

关 键 词：沙利度胺 非小细胞肺癌 晚期 化疗 辅助治疗 

分 类 号：R979.1[医药卫生—药品] R734.2[医药卫生—药学]